HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer

Michael F. Press, Richard S. Finn, David Cameron, Angelo Di Leo, Charles E. Geyer, Ivonne E. Villalobos, Angela Santiago, Roberta Guzman, Armen Gasparyan, Yanling Ma, Kathy Danenberg, Anne Marie Martin, Lisa Williams, Cristina Oliva, Steven Stein, Robert Gagnon, Michael Arbushites, Maria T. Koehler

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Purpose: Biomarkers from two randomized phase III trials were analyzed to optimize selection of patients for lapatinib therapy. Experimental Design: In available breast cancer tissue from EGF30001 (paclitaxel ± lapatinib in HER-2-negative/unknown metastatic breast cancer, n = 579) and EGF100151 (capecitabine ± lapatinib in HER-2-positive metastatic breast cancer, n = 399), HER-2 gene amplification by fluorescence in situ hybridization (FISH), HER-2 mRNA by reverse transcription-PCR (RT-PCR), HER-2 protein expression byHercepTest immunohistochemistry(IHC), epidermal growth factor receptor (EGFR) mRNA level byRT-PCR, and EGFR protein by IHC were analyzed and compared with clinical outcome. HER-2 was determined by FISH in an academic reference/research laboratoryand in a large, high-volume commercial reference laboratory. Results: The HER-2 gene was amplified in 47% (344 of 733) and IHC was 3+ in 35% (279 of 798), with significant correlation (P < 0.01) between FISH and IHC. Positive EGFR immuno-staining (IHC 1 +, 2+, or 3+) in 28% (213 of 761) correlated with EGFR mRNA levels by RT-PCR (r = 0.59; P < 0.01). HER-2 gene amplification/overexpression was associated with improved clinical outcomes (progression-free survival; P < 0.001) in both trials. A significant improvement in outcome was seen in FISH-positive and IHC 0, 1+, or 2+ patients. HER-2 mRNA expression correlated with HER-2 FISH (r = 0.83) and IHC status (r = 0.72; n = 138). No correlation was found between EGFR expression (IHC or mRNA) and responsiveness to lapatinib regardless of HER-2 status. Although a significant correlation with lapatinib responsiveness was observed among "HER-2-negative" breast cancer patients in the large, high-volume commercial reference laboratory, this was not confirmed in the academic reference/research laboratory. Conclusions: Women with HER-2-positive metastatic breast cancer benefit from lapatinib, whereas women with HER-2-negative metastatic breast cancer derive no incremental benefit from lapatinib.

Original languageEnglish (US)
Pages (from-to)7861-7870
Number of pages10
JournalClinical Cancer Research
Volume14
Issue number23
DOIs
StatePublished - Dec 1 2008

Fingerprint

erbB-2 Genes
Gene Amplification
Epidermal Growth Factor Receptor
Immunohistochemistry
Breast Neoplasms
Fluorescence In Situ Hybridization
Messenger RNA
Proteins
Polymerase Chain Reaction
Reverse Transcription
lapatinib
Paclitaxel
Research
Patient Selection
Disease-Free Survival
Research Design
Biomarkers
Staining and Labeling

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. / Press, Michael F.; Finn, Richard S.; Cameron, David; Leo, Angelo Di; Geyer, Charles E.; Villalobos, Ivonne E.; Santiago, Angela; Guzman, Roberta; Gasparyan, Armen; Ma, Yanling; Danenberg, Kathy; Martin, Anne Marie; Williams, Lisa; Oliva, Cristina; Stein, Steven; Gagnon, Robert; Arbushites, Michael; Koehler, Maria T.

In: Clinical Cancer Research, Vol. 14, No. 23, 01.12.2008, p. 7861-7870.

Research output: Contribution to journalArticle

Press, MF, Finn, RS, Cameron, D, Leo, AD, Geyer, CE, Villalobos, IE, Santiago, A, Guzman, R, Gasparyan, A, Ma, Y, Danenberg, K, Martin, AM, Williams, L, Oliva, C, Stein, S, Gagnon, R, Arbushites, M & Koehler, MT 2008, 'HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer', Clinical Cancer Research, vol. 14, no. 23, pp. 7861-7870. https://doi.org/10.1158/1078-0432.CCR-08-1056
Press, Michael F. ; Finn, Richard S. ; Cameron, David ; Leo, Angelo Di ; Geyer, Charles E. ; Villalobos, Ivonne E. ; Santiago, Angela ; Guzman, Roberta ; Gasparyan, Armen ; Ma, Yanling ; Danenberg, Kathy ; Martin, Anne Marie ; Williams, Lisa ; Oliva, Cristina ; Stein, Steven ; Gagnon, Robert ; Arbushites, Michael ; Koehler, Maria T. / HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 23. pp. 7861-7870.
@article{2f2fbc98af934c97b883f59eb418432e,
title = "HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer",
abstract = "Purpose: Biomarkers from two randomized phase III trials were analyzed to optimize selection of patients for lapatinib therapy. Experimental Design: In available breast cancer tissue from EGF30001 (paclitaxel ± lapatinib in HER-2-negative/unknown metastatic breast cancer, n = 579) and EGF100151 (capecitabine ± lapatinib in HER-2-positive metastatic breast cancer, n = 399), HER-2 gene amplification by fluorescence in situ hybridization (FISH), HER-2 mRNA by reverse transcription-PCR (RT-PCR), HER-2 protein expression byHercepTest immunohistochemistry(IHC), epidermal growth factor receptor (EGFR) mRNA level byRT-PCR, and EGFR protein by IHC were analyzed and compared with clinical outcome. HER-2 was determined by FISH in an academic reference/research laboratoryand in a large, high-volume commercial reference laboratory. Results: The HER-2 gene was amplified in 47{\%} (344 of 733) and IHC was 3+ in 35{\%} (279 of 798), with significant correlation (P < 0.01) between FISH and IHC. Positive EGFR immuno-staining (IHC 1 +, 2+, or 3+) in 28{\%} (213 of 761) correlated with EGFR mRNA levels by RT-PCR (r = 0.59; P < 0.01). HER-2 gene amplification/overexpression was associated with improved clinical outcomes (progression-free survival; P < 0.001) in both trials. A significant improvement in outcome was seen in FISH-positive and IHC 0, 1+, or 2+ patients. HER-2 mRNA expression correlated with HER-2 FISH (r = 0.83) and IHC status (r = 0.72; n = 138). No correlation was found between EGFR expression (IHC or mRNA) and responsiveness to lapatinib regardless of HER-2 status. Although a significant correlation with lapatinib responsiveness was observed among {"}HER-2-negative{"} breast cancer patients in the large, high-volume commercial reference laboratory, this was not confirmed in the academic reference/research laboratory. Conclusions: Women with HER-2-positive metastatic breast cancer benefit from lapatinib, whereas women with HER-2-negative metastatic breast cancer derive no incremental benefit from lapatinib.",
author = "Press, {Michael F.} and Finn, {Richard S.} and David Cameron and Leo, {Angelo Di} and Geyer, {Charles E.} and Villalobos, {Ivonne E.} and Angela Santiago and Roberta Guzman and Armen Gasparyan and Yanling Ma and Kathy Danenberg and Martin, {Anne Marie} and Lisa Williams and Cristina Oliva and Steven Stein and Robert Gagnon and Michael Arbushites and Koehler, {Maria T.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1158/1078-0432.CCR-08-1056",
language = "English (US)",
volume = "14",
pages = "7861--7870",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer

AU - Press, Michael F.

AU - Finn, Richard S.

AU - Cameron, David

AU - Leo, Angelo Di

AU - Geyer, Charles E.

AU - Villalobos, Ivonne E.

AU - Santiago, Angela

AU - Guzman, Roberta

AU - Gasparyan, Armen

AU - Ma, Yanling

AU - Danenberg, Kathy

AU - Martin, Anne Marie

AU - Williams, Lisa

AU - Oliva, Cristina

AU - Stein, Steven

AU - Gagnon, Robert

AU - Arbushites, Michael

AU - Koehler, Maria T.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Purpose: Biomarkers from two randomized phase III trials were analyzed to optimize selection of patients for lapatinib therapy. Experimental Design: In available breast cancer tissue from EGF30001 (paclitaxel ± lapatinib in HER-2-negative/unknown metastatic breast cancer, n = 579) and EGF100151 (capecitabine ± lapatinib in HER-2-positive metastatic breast cancer, n = 399), HER-2 gene amplification by fluorescence in situ hybridization (FISH), HER-2 mRNA by reverse transcription-PCR (RT-PCR), HER-2 protein expression byHercepTest immunohistochemistry(IHC), epidermal growth factor receptor (EGFR) mRNA level byRT-PCR, and EGFR protein by IHC were analyzed and compared with clinical outcome. HER-2 was determined by FISH in an academic reference/research laboratoryand in a large, high-volume commercial reference laboratory. Results: The HER-2 gene was amplified in 47% (344 of 733) and IHC was 3+ in 35% (279 of 798), with significant correlation (P < 0.01) between FISH and IHC. Positive EGFR immuno-staining (IHC 1 +, 2+, or 3+) in 28% (213 of 761) correlated with EGFR mRNA levels by RT-PCR (r = 0.59; P < 0.01). HER-2 gene amplification/overexpression was associated with improved clinical outcomes (progression-free survival; P < 0.001) in both trials. A significant improvement in outcome was seen in FISH-positive and IHC 0, 1+, or 2+ patients. HER-2 mRNA expression correlated with HER-2 FISH (r = 0.83) and IHC status (r = 0.72; n = 138). No correlation was found between EGFR expression (IHC or mRNA) and responsiveness to lapatinib regardless of HER-2 status. Although a significant correlation with lapatinib responsiveness was observed among "HER-2-negative" breast cancer patients in the large, high-volume commercial reference laboratory, this was not confirmed in the academic reference/research laboratory. Conclusions: Women with HER-2-positive metastatic breast cancer benefit from lapatinib, whereas women with HER-2-negative metastatic breast cancer derive no incremental benefit from lapatinib.

AB - Purpose: Biomarkers from two randomized phase III trials were analyzed to optimize selection of patients for lapatinib therapy. Experimental Design: In available breast cancer tissue from EGF30001 (paclitaxel ± lapatinib in HER-2-negative/unknown metastatic breast cancer, n = 579) and EGF100151 (capecitabine ± lapatinib in HER-2-positive metastatic breast cancer, n = 399), HER-2 gene amplification by fluorescence in situ hybridization (FISH), HER-2 mRNA by reverse transcription-PCR (RT-PCR), HER-2 protein expression byHercepTest immunohistochemistry(IHC), epidermal growth factor receptor (EGFR) mRNA level byRT-PCR, and EGFR protein by IHC were analyzed and compared with clinical outcome. HER-2 was determined by FISH in an academic reference/research laboratoryand in a large, high-volume commercial reference laboratory. Results: The HER-2 gene was amplified in 47% (344 of 733) and IHC was 3+ in 35% (279 of 798), with significant correlation (P < 0.01) between FISH and IHC. Positive EGFR immuno-staining (IHC 1 +, 2+, or 3+) in 28% (213 of 761) correlated with EGFR mRNA levels by RT-PCR (r = 0.59; P < 0.01). HER-2 gene amplification/overexpression was associated with improved clinical outcomes (progression-free survival; P < 0.001) in both trials. A significant improvement in outcome was seen in FISH-positive and IHC 0, 1+, or 2+ patients. HER-2 mRNA expression correlated with HER-2 FISH (r = 0.83) and IHC status (r = 0.72; n = 138). No correlation was found between EGFR expression (IHC or mRNA) and responsiveness to lapatinib regardless of HER-2 status. Although a significant correlation with lapatinib responsiveness was observed among "HER-2-negative" breast cancer patients in the large, high-volume commercial reference laboratory, this was not confirmed in the academic reference/research laboratory. Conclusions: Women with HER-2-positive metastatic breast cancer benefit from lapatinib, whereas women with HER-2-negative metastatic breast cancer derive no incremental benefit from lapatinib.

UR - http://www.scopus.com/inward/record.url?scp=59449106972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59449106972&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-1056

DO - 10.1158/1078-0432.CCR-08-1056

M3 - Article

C2 - 19047115

AN - SCOPUS:59449106972

VL - 14

SP - 7861

EP - 7870

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 23

ER -